We recently found out that Norges Bank Investment Mgt. accumulated Kerx holdings of 2.1 million shares. The following an excerpt from an article...
“Deutsche Bank will slash 9,000 full-time jobs, 6,000 contractor positions and sell operations with 20,000 more workers. By 2018, the cuts and disposals are to shrink the bank's workforce from around 103,000 to 77,000. The major shareholders in the bank are Norges Bank Investment Management and their American Partner BlackRock, reports Nordens Nyheter ...”
As per my last prior post (link below), there’s seems to be a close relationship between BlackRock and Sanofi. The excerpt above shows a connection between BlackRock and Norges Bank Investment. IMO, Vanguard, State Street, Clearbridge etc. in the mix.
__________________________________
Let’s not forget that Daniel P. Regan (Keryx’s BOD leadership, imo) and Greg Madison are ex-Sanofi Genzyme (SG) and worked together. (Regan’s career at SG included his appointment as Global General Manager, Senior Vice President of the Renal franchise, with direct responsibility for all aspects of worldwide renal commercial operations, including the Renagel®/Renvela® phosphate binder franchise and the worldwide launch of Renvela®, growing the renal franchise to global revenue approaching $1 billion).
Now, John P. Butler, Keryx’s ex-BOD Director and Baupost’s guy, was replaced by Mark J. Enyedy. (Enyedy served 15 years at Sanofi Genzyme (SG). He began his career at SG in 1996 as Corporate Counsel where he was responsible for overseeing corporate collaborations, merger and acquisition activities, financings and securities law compliance.) Keryx’s Corporate Counsel Brian Adams gone.
Here’s the thing, again, as per my prior post (link below), Sanofi could be making a power move to acquire controlling ownership of Keryx. Now, could there be a hostile environment between Sanofi and Baupost? - situation directly related to Butler exiting Keryx and signing with Vifor Fresenius? Could it go back even further (for those of you who know) to Vifor Fresenius snatching Relypsa from Sanofi with Butler being Relypsa BOD Director.?
IF Sanofi making a power move to acquire controlling ownership of Keryx (price being kept in check), again, let’s not forget Regan, Madison, and Enyedy are ex-SG. Hostile environment with Baupost? Who knows, conjecture, after all, Baupost just wants his ROI imo, if it’s there, no problem.
Hey, poster 2Cents, 3 pennies less than a nickel PUNK, you have anything to contribute, PUNK?
ALL IMO
